球客岛APP官网

CAR-T therapy is an immunotherapy that uses gene engineering technologies such as viral vectors or electroporation to implant chimeric antigen receptors (CARs) that specifically recognize tumor-associated antigens and simultaneously activate T cells into the patient's T lymphocytes. These CAR-T cells are then purified and expanded in vitro before being reinfused, allowing them to inhibit and kill tumors. Shenzhen Cell Cell Technology Co., Ltd. provides R&D and outsourced production services for CAR-T cells targeting different targets. Currently, it has successfully used its self-produced industrial-grade retroviral vectors to prepare multiple CAR-T cells targeting CD19, CD38, and BCMA-CD38 dual targets, with transduction efficiencies exceeding 70%. The company can provide a complete service from T lymphocyte collection, transduction of tumor-targeting viral vectors, CAR-T cell expansion, safety testing, and release. Currently, it provides GMP-grade CAR-T cell production services to institutions such as Huazhong University of Science and Technology and Shenzhen Hospital.

Customized R&D is available to meet client needs, with research-grade retroviral vectors produced in 500 mL increments. The company provides comprehensive CDMO solutions, encompassing antibody screening, vector construction, viral vector packaging, CAR-T cell preparation, and in vitro/in vivo CAR-T cell activity validation. Furthermore, the company offers CAR-specific retroviral vector products targeting various tumor targets, such as BCMA, CD19, CD38, CD22, and EGFR/EGFRV III, all capable of efficiently transducing human primary T cells. The CD38 CAR, in particular, is a fully human anti-CD38 scFv structure obtained through phage display scFv antibody library screening, possessing independent intellectual property rights.

CAR-NK cells are easily expandable and modifiable allogeneic effector cells, enhancing the versatility and simplicity of treatment while compensating for the weakened autoimmune cells in patients with advanced cancer. CAR-NK cells kill target cells through CAR-dependent and NK cell receptor-dependent mechanisms, eliminating tumor cells positive for tumor-associated antigens or expressing NK cell receptor ligands. Shenzhen Cell Valley will provide a full-process service from NK cell collection and transduction to expansion, with transduction efficiency of exogenous genes exceeding 50%, helping clients accelerate their research in the CAR-NK field.

Lentiviral vectors are viral vector systems modified from HIV-1 that can effectively integrate exogenous genes or exogenous shRNAs into the host chromosome, thereby achieving persistent expression of the target sequence. Lentivirals have become one of the commonly used vector forms for expressing exogenous genes or exogenous shRNAs and are gaining increasingly widespread application. CellValley can provide customized lentiviral vector services targeting various tumor targets, such as BCMA, CD19, CD38, CD22, EGFR/EGFRVIII, etc.

CAR-M cell therapy involves transferring edited, specific CAR genes into macrophages, enabling them to bind to the surface of tumor cells through specific antigen identification and subsequently activate macrophage activity targeting tumor cells. Genetically engineered CAR-M cells can not only target and phagocytose tumor cells but also alter the tumor microenvironment by secreting pro-inflammatory cytokines and present tumor antigens to T cells, activating the T cell immune response against the tumor. The advent of CAR-M has opened up new possibilities for treating solid tumors: modifying human macrophages with specific CARs to enhance phagocytic activity and macrophage antigen presentation against tumors. Shenzhen Cell Valley will collaborate with clients to explore the most suitable CAR structures, exogenous genes, and transduction conditions for macrophages, contributing to CAR-M research and development.

Adeno-associated viruses (AAVs) are a class of simple, non-enveloped, single-stranded DNA-deficient viruses capable of infecting both dividing and non-dividing cells. They can package large genes, making them a preferred tool for gene overexpression. AAVs are characterized by good safety, a broad host cell range, low immunogenicity, and long-term expression of exogenous genes in vivo. Shenzhen Cell Valley provides adeno-associated virus vectors of various specifications and serotypes, including single-promoter single-gene, single-promoter multi-gene, and dual-promoter multi-gene subtypes.

Astrocytes are the most abundant cell type in the brain, playing a crucial role in regulating extracellular ions and neurotransmitter levels, modulating synaptic activity, maintaining glutamate homeostasis, and preserving the integrity of the blood-brain barrier. Upon stimulation such as trauma or infection, astrocytes are rapidly activated, forming reactive astrocytes characterized by proliferation, hypertrophy, and high expression of intermediate filament proteins (including glial fibrillary acidic protein, vimentin, and nestin). Studies have shown that reactive astrocytes possess both neurotoxic and neurotrophic effects. Shenzhen Cell Valley provides a full-process service from neural stem cell differentiation to Astrocytes, purification, quality control, and release. Our products are highly pure, quality-controlled, and safe. We collaborate with research institutes, medical institutions, and enterprises to provide solutions for preclinical research and innovative breakthroughs in Astrocytes.

Non-viral vectors utilize the physicochemical properties of non-viral vector materials to mediate gene transfer. Shenzhen Cell Valley primarily provides its unique non-viral gene engineering technology (PiggyBac transposon modification), a core technology for CAR-T therapy development. PiggyBac can effectively deliver large amounts of genetic material to T cells, producing CAR-T products with a high percentage of stem memory cells. This includes various subtypes such as single-promoter single-gene, single-promoter multi-gene, and dual-promoter multi-gene.